Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) enters a critical six-day stretch with Q2 earnings due July 31, and an FDA ...

The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 ...

Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

The FDA had previously rejected Moderna's application, refusing even to review it after concluding Moderna hadn't done sufficient safety testing. Now, Moderna is promising to do additional testing to ...

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.

Moderna (MRNA) snapped a six-session winning streak on Monday, with shares closing down 7.13% at $59.40. Despite the decline, the stock has been one of the market's standout performers recently. Over ...

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. 10 stocks we like ...

CHONGQING, CHINA - FEBRUARY 3: In this photo illustration, a smartphone displays the logo of Moderna, Inc. (NASDAQ: MRNA), a U.S.-based biotechnology company specializing in messenger RNA (mRNA) ...

Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. 10 stocks we like better than Moderna › A few ...